Allergan to merge with Pfizer after a 90% sales increase

Allergan reported what it described as “continued exceptional performance” with sales up by 90 percent to $4.1 billion for the quarter ended Sept. 30 as compared to the previous year's third quarter. The performance was driven by growth in the company's U.S. Brands, medical aesthetics, international brands and Anda distribution ...

To continue reading this article subscribe now

Already an Eyewear Intelligence subscriber? Sign in here.

barrier_image_OIC

Become a member today for full access from just €6,70 a week!

Buying a membership today will give you:

  • Unlimited access to ewintelligence.com - all insight and analysis available online
  • Our executive edition of Eyewear Intelligence (Digital Edition) - the must-read for all decision-makers in the industry
  • Weekly E-mail Briefing from the Chief Editor with the lastest analysis and most important industry developments
  • Case studies and best practices on business challenges
  • Guest chronicles, interviews, insights from industry experts and leaders that are shaping the future of the industry
  • Access to over 11,500 articles and analyses in the archive
  • Personal library to save articles and track your key content
  • Powerful search and intuitive navigation

To continue reading this article register now.